Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.

Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM.

Immunology. 2013 Mar;138(3):280-92. doi: 10.1111/imm.12037.

PMID:
23198850
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.

Sorensen EW, Gerber SA, Frelinger JG, Lord EM.

J Immunol. 2010 Feb 15;184(4):1858-66. doi: 10.4049/jimmunol.0903210. Epub 2010 Jan 8.

PMID:
20061409
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.

Song S, Wang Y, Wang J, Lian W, Liu S, Zhang Z, Liu F, Wei L.

Eur J Cancer. 2012 Sep;48(14):2252-9. doi: 10.1016/j.ejca.2011.12.009. Epub 2012 Jan 7.

PMID:
22230748
[PubMed - indexed for MEDLINE]
4.

The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.

Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Søgaard M, Andersson J, Andersson U.

Br J Cancer. 1999 Sep;81(2):359-66.

PMID:
10496366
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.

García-Hernández ML, Hernández-Pando R, Gariglio P, Berumen J.

Immunology. 2002 Feb;105(2):231-43.

PMID:
11872099
[PubMed - indexed for MEDLINE]
Free PMC Article
6.
7.

Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice.

Hayata K, Iwahashi M, Ojima T, Katsuda M, Iida T, Nakamori M, Ueda K, Nakamura M, Miyazawa M, Tsuji T, Yamaue H.

PLoS One. 2013;8(1):e53131. doi: 10.1371/journal.pone.0053131. Epub 2013 Jan 25.

PMID:
23372655
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.

Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH.

Int J Cancer. 2004 Apr 20;109(4):499-506.

PMID:
14991570
[PubMed - indexed for MEDLINE]
9.

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10399-404.

PMID:
8816812
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.

Song S, Zhang K, You H, Wang J, Wang Z, Yan C, Liu F.

Clin Exp Immunol. 2010 Oct;162(1):75-83. doi: 10.1111/j.1365-2249.2010.04226.x.

PMID:
20735440
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.

Kim TS, Xu WS, Sun T, Cohen EP.

Melanoma Res. 1995 Aug;5(4):217-27.

PMID:
7496156
[PubMed - indexed for MEDLINE]
12.

Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.

Kobori H, Hashiguchi M, Piao J, Kato M, Ritprajak P, Azuma M.

Immunology. 2010 Jul;130(3):363-73. doi: 10.1111/j.1365-2567.2009.03236.x. Epub 2010 Feb 5.

PMID:
20141543
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Gene transfer of a hybrid interleukin-1 beta gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo.

Björkdahl O, Wingren AG, Hedhund G, Ohlsson L, Dohlsten M.

Cancer Immunol Immunother. 1997 Jul;44(5):273-81.

PMID:
9247562
[PubMed - indexed for MEDLINE]
14.

Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.

Dobrzanski MJ, Reome JB, Dutton RW.

J Immunol. 2001 Jul 1;167(1):424-34.

PMID:
11418679
[PubMed - indexed for MEDLINE]
Free Article
15.

Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18.

Nagai H, Hara I, Horikawa T, Fujii M, Kurimoto M, Kamidono S, Ichihashi M.

Cancer Invest. 2000;18(3):206-13.

PMID:
10754989
[PubMed - indexed for MEDLINE]
16.

Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.

Kuhn S, Hyde EJ, Yang J, Rich FJ, Harper JL, Kirman JR, Ronchese F.

J Immunol. 2013 Aug 15;191(4):1984-92. doi: 10.4049/jimmunol.1301135. Epub 2013 Jul 15.

PMID:
23858033
[PubMed - indexed for MEDLINE]
Free Article
17.

Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.

Tamada K, Harada M, Okamoto T, Takenoyama M, Ito O, Matsuzaki G, Nomoto K.

Cancer Immunol Immunother. 1995 Dec;41(6):339-47.

PMID:
8635191
[PubMed - indexed for MEDLINE]
18.

Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.

Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J.

Immunol Cell Biol. 2008 Aug-Sep;86(6):506-14. doi: 10.1038/icb.2008.27. Epub 2008 Apr 8.

PMID:
18392040
[PubMed - indexed for MEDLINE]
19.

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.

Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92. doi: 10.1073/pnas.1203479109. Epub 2012 Apr 2.

PMID:
22474386
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.

Wei H, Zheng X, Lou D, Zhang L, Zhang R, Sun R, Tian Z.

Mol Immunol. 2005 May;42(9):1023-31. Epub 2004 Nov 23.

PMID:
15829292
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk